QBIO News and Press, Q BioMed Inc From 02/08/19

NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (OTCQB: QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally. The illness often remains undetected long after significant vision loss has already occur...

NEW YORK , Feb. 7, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. Expecting several corporate developments and news events, the C...

NEW YORK , Feb. 1, 2019 /PRNewswire/ --  Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today the Company's CEO Denis Corin will deliver a corporate presentation and conduct one-on-one meetings with investors and potential business partners at th...

NEW YORK, NY / ACCESSWIRE / January 28, 2019 / Shares of Q BioMed Inc. (OTCQB: QBIO) rose on heavy volume after the company announced that a new collaboration among researchers at McMaster University, Mannin Research and the emerging biotechnology accelerator, focuses on ophthalmic drug de...

NEW YORK , January 25, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that its technology partner, Mannin Research , has initiated a collaboration with McMaster University of Ontario, Canada . The collaboration is focused ...